RxDoctor Payments Data

Annisa Jamil, MD

Glaucoma Specialist · Seattle, WANPI 1629006135

Payments from drug & device makers

$3,277in general payments, 2019–2025

Across 164 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$891
  • Alcon$506
  • Bausch & Lomb Americas Inc.$336
  • Sun Pharmaceutical Industries Inc.$335
  • Glaukos Corporation$196
  • Rxsight Inc$189
  • plus $824 from 15 others

What the payments were for

  • Food & beverage$3,17597%
  • Education$582%
  • Gifts$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Washingtonto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$399,229
Medicare patients
595
Services billed
4,678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyzultaLatanoprostene Bunod538$276,116
RhopressaNetarsudil Mesylate338$180,269
LumiganBimatoprost150$91,994
RestasisCyclosporine71$61,543
CombiganBrimonidine Tartrate/Timolol103$48,570
SimbrinzaBrinzolamide/Brimonidine Tart135$41,789
RocklatanNetarsudil Mesylat/Latanoprost43$31,907
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol188$28,474
Alphagan PBrimonidine Tartrate57$21,755
MieboPerfluorohexyloctane/Pf22$18,993
Difluprednate183$17,973
Dorzolamide-TimololDorzolamide/Timolol/Pf93$16,810
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat721$12,481
Travoprost79$11,953
TafluprostTafluprost/Pf55$11,789

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Vyzulta, Miebo$336$295,109560 claims
AbbVieLumigan, Restasis, Combigan, Alphagan P$891$223,863381 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$76$212,177381 claims
AlconSimbrinza, Azopt$506$45,820146 claims
Akorn, Inc.Zioptan$39$6,03712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Washingtonon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Seattle

Where these figures come from

Is this you, or does something look wrong? →